<DOC>
	<DOCNO>NCT02890069</DOCNO>
	<brief_summary>The purpose study combine PDR001 checkpoint inhibitor several agent immunomodulatory activity identify dos schedule combination therapy preliminarily assess safety , tolerability , pharmacological clinical activity combination .</brief_summary>
	<brief_title>A Study PDR001 Combination With LCL161 , Everolimus Panobinostat</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Written inform consent prior procedure Patients advanced/metastatic cancer , measurable disease determine RECIST version 1.1 , progress despite standard therapy intolerant SOC , standard therapy exists . Patients must fit one follow group : • CRC •NSCLC • TNBC ECOG ≤ 2 Patient must site disease biopsy , candidate tumor biopsy accord institution 's guideline . Patient must willing undergo new tumor biopsy screening , therapy study . Prior therapy PD1/PDL1 inhibitor allow provided toxicity attribute prior PD1 PDL1directed therapy lead discontinuation therapy . Presence symptomatic central nervous system ( CNS ) metastases , CNS metastases require local CNSdirected therapy within prior 2 week . History severe hypersensitivity reaction mAbs . Out range lab value define protocol Impaired cardiac function clinically significant cardiac disease Active , know suspected autoimmune disease Human Immunodeficiency Virus ( HIV ) , active Hepatitis C ( HCV ) virus . Escalation : active Hepatitis B ( HBV ) ; Expansion : Patients Chronic HBV currently medication exclude . Impairment gastrointestinal ( GI ) function Malignant disease , treat study Systemic anticancer therapy within 2 week first dose study treatment . For cytotoxic agent major delay toxicity CTLA4 antagonist , washout period 6 week . Active infection require systemic antibiotic therapy . Patients require chronic treatment systemic steroid therapy , replacement dose steroid . Patients receive systemic treatment immunosuppressive medication . Major surgery within 2 week first dose study treatment Radiotherapy within 2 week first dose study drug Participation interventional , investigational study within 2 week first dose study treatment . Presence ≥ CTCAE grade 2 toxicity ( except alopecia , peripheral neuropathy ototoxicity , exclude ≥ CTCAE grade 3 ) due prior therapy . Additional exclusion criterion PDR001/LCL161 Patients require medication metabolize CYP3A4/5 narrow therapeutic index medication CYP3A4 substrates cause QT prolongation Patients require treatment strong CYP2C8 inhibitor Additional exclusion criterion PDR001/Everolimus Patients require treatment moderate CYP3A4 inhibitor Patients require treatment strong CYP3A4 inhibitor inducer Additional exclusion criterion PDR001/Panobinostat Patient receive DAC inhibitor Patient need valproic acid study within 5 day prior first dose Patients require medication sensitive CYP2D6 substrates antiarrhythmic drugs/QTprolonging drug Patients require strong inhibitor inducer CYP3A4 Clinically significant , uncontrolled heart disease and/or recent cardiac event within 6 month prior study Unresolved diarrhea ≥ CTCAE grade 2 medical condition associate chronic diarrhea Taking medication QT prolongation risk interval induce Torsade de point Other protocoldefined inclusion exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>PDR001</keyword>
	<keyword>CRC</keyword>
	<keyword>TNBC</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Immunomodulation</keyword>
	<keyword>Biomarkers</keyword>
	<keyword>Bayesian logistic regression model</keyword>
</DOC>